Plasma Protein Therapeutics Market

The global plasma protein therapeutics market size was estimated to be US$ 24 Billion in 2022 and is expected to reach US$ 41 Billion by 2032 at a CAGR of 5.6%. 

The plasma protein therapeutics market is highly competitive and is governed by stringent regulations worldwide. The plasma collection standards are high in the developed geographies and follows a strict regulatory framework to maintain operational quality. The fractionation process is monitored by the health authorities to prevent poor quality of plasma and ensure that the source plasma is not contaminated with infectious agent such as Parvovirus B, hepatitis A, B and C, and HIV.

The plasma protein therapy cycle is complex and is strictly monitored to maintain process safety & efficacy, donor safety, biological license, compliance and pharmacovigilance. The demand for immunoglobulin is increasing significantly across the globe due to increasing incidences of the primary immunodeficiencies (PID). This has resulted in increased number of clinical applications such as autoimmune, and acute inflammatory disorders.

The increasing demand for plasma protein therapeutics for treatment of autoimmune neurologic diseases, acute cardiomyopathy, multifocal motor neuropathy (MMN), hemolytic disease of the newborn, autoimmune mucocutaneous blistering diseases, and acute panautonomic polyneuropathy is the prime factor towards the growth of the global plasma protein therapeutics market.

North America contributed the largest share to the global plasma protein therapeutics market in 2019 owing to rising demand, expanding geriatric population, and availability of robust plasma donation infrastructure. The leading players across North America are inclined towards acquisition of small plasma donation centers to expand their service network and are investing significantly on the development of new plasma donation centers. This has intensified the competition in the market and is anticipated to benefit the patients suffering from plasma deficiency.

Asia Pacific is anticipated to be the fastest growing market for plasma protein therapeutics during the forecast period. Increasing number of patients suffering from primary immunodeficiencies (PID) & hemophilia across the major countries, rising awareness regarding the plasma transplant solutions and expanding healthcare infrastructure are expected to bolster the plasma protein therapeutics market in Asia Pacific. Additionally, the government authorities are actively engaged in spreading awareness about plasma donation and are offering incentives to the donors, which is anticipated to support the growth of Asia Pacific plasma protein therapeutics.

The report titled “Plasma Protein Therapeutics Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global plasma protein therapeutics market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global plasma protein therapeutics market is segmented based on product type, applications, and geography. Based on product type, the global plasma protein therapeutics market is segmented into immunoglobulin, albumin, plasma derived factor VIII, and others. Based on applications, the global plasma protein therapeutics market is segmented into hemophilia, idiopathic thrombocytopenic purpura, primary immunodeficiencies, and others. Based on geography, the global plasma protein therapeutics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on plasma protein therapeutics products. Further, market share of prominent companies in the global plasma protein therapeutics market would also be estimated. The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the plasma protein therapeutics companies.

The global plasma protein therapeutics market study would take into consideration the participants engaged throughout the ecosystem of the market, along with their contribution. Product portfolio would focus on all the products under the plasma protein therapeutics business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global plasma protein therapeutics market.

Major players active in the global plasma protein therapeutics market include Baxter International Inc., Biotest Pharmaceuticals Corporation, China Biologic Products, Inc., CSL Behring, GRIFOLS, S.A, Kedrion S.p.A., Octapharma USA, Inc., and Shire Plc.

Market Segmentation:

By Product

• Albumin
• Immunoglobulin
• Factor VIII
• others

By Application

• Hemophilia
• Primary Immunodeficiency Disorder (PID)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

By Geography:

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
• South America
  • Brazil